About Careers Internship MedBlog Contact us

Genetic Marker can Help Predict the Risk of Ovarian Cancer

by Savitha C Muppala on July 22, 2010 at 10:28 PM
Font : A-A+

 Genetic Marker can Help Predict the Risk of Ovarian Cancer

Scientists from the Yale University have found a new genetic marker which can predict the risk of developing ovarian cancer.

The research team showed that a variant of the KRAS oncogene was present in 25 percent of all ovarian cancer patients.


This variant was also found in 61 percent of ovarian cancer patients with a family history of breast and ovarian cancer, suggesting that it could be a new marker of ovarian cancer risk for these families, according to the researchers.

"For many women out there with a strong family history of ovarian cancer who previously have had no identified genetic cause for their family's disease; this might be it for them," said Joanne B. Weidhaas, associate professor of therapeutic radiology, and co-senior author of the study.

"Our findings support that the KRAS-variant is an new genetic marker of ovarian cancer risk," she added.

To confirm that the KRAS-variant was a genetic marker of ovarian cancer risk, Weidhaas and co-senior author Frank Slack studied women with ovarian cancer who also had evidence of a hereditary breast and ovarian cancer syndrome.

All these women had strong family history of cancer, but only half in their study had known genetic markers of ovarian cancer risk, BRCA1 or BRCA2 mutations.

Unlike women with BRCA mutations who develop ovarian cancer at a younger age, women with the KRAS-variant tend to develop cancer after menopause.

Because ovarian cancer is difficult to diagnose and thus usually found at advanced stages, finding new markers of increased ovarian cancer risk is critical, note the researchers.

The research was published in the July 20, 20010 edition of the journal Cancer Research.

Source: ANI


Recommended Readings

Latest Cancer News

Combination Therapy may Benefit Leukemia Patients
The new study uncovers the efficacy of fixed-duration combination treatment in patients with high-risk leukemia.
 Myelofibrosis: New Drugs to Revolutionize Treatment
The approvals of pipeline drugs such as momelotinib and Vonjo for myelofibrosis (a rare type of blood cancer) over some time will handle the critical unmet needs.
 Blood Vessels Can Kill Cancer Cells and Stop Breast Cancer Spread
New study highlights the dual role that blood vessels can play in cancer immunotherapy and eliciting anti-tumor immune responses or even preventing breast cancer spread.
 Weed Killer Agent Orange May Increase the Risk of Blood Cancer Among Veterans
New study evaluated the association between exposure to the chemical agent orange and the development of blood cancer with increased bleeding and blood clot formation.
Two Years: Optimal Duration of Immunotherapy in Advanced Lung Cancer
Study suggests two-year immunotherapy treatment for advanced lung cancer may be reasonable
View All
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close

Genetic Marker can Help Predict the Risk of Ovarian Cancer Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests